Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
46
NKTR Quote, Financials, Valuation and Earnings
Last price:
$44.55
Seasonality move
:
7.44%
Day range:
$43.01 - $44.91
52-week range:
$6.48 - $66.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
45.88x
P/B ratio:
9.05x
Volume:
406.3K
Avg. volume:
855.1K
1-year change:
211.82%
Market cap:
$769.7M
Revenue:
$98.4M
EPS (TTM):
-$4.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$10.1M | -$2.59 | -64.24% | -1474.64% | $114.43 |
|
AMGN
Amgen, Inc.
|
$8.7B | $5.04 | 4.54% | 310.03% | $325.88 |
|
INSM
Insmed, Inc.
|
$191.7M | -$1.18 | 66.86% | -2.57% | $214.78 |
|
LYEL
Lyell Immunopharma, Inc.
|
-- | -$2.30 | -100% | -1177.78% | $29.67 |
|
OWLT
Owlet, Inc.
|
$26.2M | -$0.12 | 26% | -81.11% | $14.88 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$59.3M | $0.80 | 15.36% | 30.92% | $51.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$44.49 | $114.43 | $769.7M | -- | $0.00 | 0% | 45.88x |
|
AMGN
Amgen, Inc.
|
$332.93 | $325.88 | $179.3B | 25.74x | $2.38 | 2.86% | 5.02x |
|
INSM
Insmed, Inc.
|
$177.88 | $214.78 | $37.9B | -- | $0.00 | 0% | 75.70x |
|
LYEL
Lyell Immunopharma, Inc.
|
$35.09 | $29.67 | $519.6M | -- | $0.00 | 0% | 127,243.53x |
|
OWLT
Owlet, Inc.
|
$15.53 | $14.88 | $428.3M | -- | $0.00 | 0% | 2.60x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$44.01 | $51.20 | $798.8M | 7.14x | $0.00 | 0% | 2.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
LYEL
Lyell Immunopharma, Inc.
|
13.89% | 2.501 | 22.07% | 10.03x |
|
OWLT
Owlet, Inc.
|
-182.74% | 3.918 | 16.06% | 0.85x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 2.066 | 11.84% | 1.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
LYEL
Lyell Immunopharma, Inc.
|
-$2.6M | -$38.8M | -75.65% | -86.7% | -258960% | -$28.6M |
|
OWLT
Owlet, Inc.
|
$16.2M | $1.2M | -- | -- | 3.8% | -$2.6M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
Nektar Therapeutics vs. Competitors
-
Which has Higher Returns NKTR or AMGN?
Amgen, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 33.55%. Nektar Therapeutics's return on equity of -327.67% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About NKTR or AMGN?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 157.2%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -2.12%. Given that Nektar Therapeutics has higher upside potential than Amgen, Inc., analysts believe Nektar Therapeutics is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 AMGNAmgen, Inc.10 15 2 -
Is NKTR or AMGN More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock NKTR or AMGN?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.86% to investors and pays a quarterly dividend of $2.38 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or AMGN?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Nektar Therapeutics's net income of -$35.5M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.88x versus 5.02x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M AMGNAmgen, Inc.5.02x 25.74x $9.6B $3.2B
-
Which has Higher Returns NKTR or INSM?
Insmed, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -259.95%. Nektar Therapeutics's return on equity of -327.67% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About NKTR or INSM?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 157.2%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 20.84%. Given that Nektar Therapeutics has higher upside potential than Insmed, Inc., analysts believe Nektar Therapeutics is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 INSMInsmed, Inc.17 1 0 -
Is NKTR or INSM More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock NKTR or INSM?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or INSM?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Nektar Therapeutics's net income of -$35.5M is higher than Insmed, Inc.'s net income of -$370M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.88x versus 75.70x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M INSMInsmed, Inc.75.70x -- $142.3M -$370M
-
Which has Higher Returns NKTR or LYEL?
Lyell Immunopharma, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -258973.33%. Nektar Therapeutics's return on equity of -327.67% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M LYELLyell Immunopharma, Inc.-17006.67% -$2.13 $382.2M -
What do Analysts Say About NKTR or LYEL?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 157.2%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could fall by -15.46%. Given that Nektar Therapeutics has higher upside potential than Lyell Immunopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Lyell Immunopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 LYELLyell Immunopharma, Inc.2 0 0 -
Is NKTR or LYEL More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NKTR or LYEL?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or LYEL?
Nektar Therapeutics quarterly revenues are $11.8M, which are larger than Lyell Immunopharma, Inc. quarterly revenues of $15K. Nektar Therapeutics's net income of -$35.5M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.88x versus 127,243.53x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M LYELLyell Immunopharma, Inc.127,243.53x -- $15K -$38.8M
-
Which has Higher Returns NKTR or OWLT?
Owlet, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 12.58%. Nektar Therapeutics's return on equity of -327.67% beat Owlet, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M OWLTOwlet, Inc.50.51% $0.13 -$13.7M -
What do Analysts Say About NKTR or OWLT?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 157.2%. On the other hand Owlet, Inc. has an analysts' consensus of $14.88 which suggests that it could fall by -4.22%. Given that Nektar Therapeutics has higher upside potential than Owlet, Inc., analysts believe Nektar Therapeutics is more attractive than Owlet, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 OWLTOwlet, Inc.5 0 0 -
Is NKTR or OWLT More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.734, suggesting its more volatile than the S&P 500 by 73.364%.
-
Which is a Better Dividend Stock NKTR or OWLT?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or OWLT?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Nektar Therapeutics's net income of -$35.5M is lower than Owlet, Inc.'s net income of $4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.88x versus 2.60x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M OWLTOwlet, Inc.2.60x -- $32M $4M
-
Which has Higher Returns NKTR or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 40.17%. Nektar Therapeutics's return on equity of -327.67% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics98.34% -$1.87 $252.2M RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M -
What do Analysts Say About NKTR or RIGL?
Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 157.2%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 16.34%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics6 1 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is NKTR or RIGL More Risky?
Nektar Therapeutics has a beta of 1.268, which suggesting that the stock is 26.844% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.
-
Which is a Better Dividend Stock NKTR or RIGL?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or RIGL?
Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Nektar Therapeutics's net income of -$35.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 7.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 45.88x versus 2.87x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics45.88x -- $11.8M -$35.5M RIGLRigel Pharmaceuticals, Inc.2.87x 7.14x $69.5M $27.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
